Genetically delivered antibody protects against West Nile virus.
Gene-based delivery of recombinant antibody genes is a promising therapeutic strategy offering numerous advantages including sustained antibody levels, better safety profile and lower production cost. Here we describe generation of a recombinant antibody Fc-9E2 comprising a fusion protein between human Fc of IgG1 and a single-chain Fv derived from a hybridoma 9E2 secreting a mAb neutralizing West Nile virus (WNV). Fc-9E2 was shown to retain parental mAb's specificity and WNV-neutralizing capacity. Adenovirus-mediated in vivo delivery of the antibody gene resulted in sustained Fc-9E2 serum levels leading to abrogation of lethal WNV infection in an animal model.
Pereboev
Alexander
A
Division of Human Gene Therapy, Department of Medicine, University of Alabama at Birmingham 35294-2172, USA. pereboev@uab.edu
Borisevich
Viktoriya
V
Tsuladze
George
G
Shakhmatov
Mikhail
M
Hudman
Deborah
D
Kazachinskaia
Elena
E
Razumov
Ivan
I
Svyatchenko
Viktor
V
Loktev
Valery
V
Yamshchikov
Vladimir
V
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D000914:Antibodies, Viral / Q000235:genetics* / Q000276:immunology*; D005260:Female; D018014:Gene Transfer Techniques; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D011993:Recombinant Fusion Proteins / Q000276:immunology; D014901:West Nile Fever / Q000276:immunology* / Q000517:prevention & control* / Q000821:virology; D014902:West Nile virus / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D011993:Recombinant Fusion Proteins